FIELD: chemistry.
SUBSTANCE: invention refers to compounds of formula (I) or their pharmaceutically acceptable salts.
EFFECT: technical result is obtaining novel compounds of formula (I), as well as pharmaceutical compositions based thereon, which are simultaneously inhibitors of the enzyme hydrolase amides of fatty acids (FAAH) and dopamine receptor (D3DR) D3 modulators, suitable for treating or preventing mediated disorders.
20 cl, 1 tbl, 45 ex
Title | Year | Author | Number |
---|---|---|---|
THERAPEUTIC AGENTS AIMED AT SHORTENED PROTEINS OF ADENOMATOUS POLYPOSIS COLI (APC) | 2014 |
|
RU2727516C2 |
TAXANE DERIVATIVES, METHOD OF THEIR SYNTHESIS, PHARMACEUTICAL COMPOSITION AND METHOD OF TREATMENT | 1994 |
|
RU2137764C1 |
HETEROCYCLIC COMPOUNDS AND METHODS OF APPLICATION | 2009 |
|
RU2525116C2 |
BICYCLIC COMPOUND AND USE THEREOF FOR SUV39H2 INHIBITION | 2016 |
|
RU2729187C1 |
N- (PHENYLSULPHONYL) BENZAMIDES AND RELATED COMPOUNDS AS BCL-2 INHIBITORS | 2017 |
|
RU2744358C2 |
CHEMICAL COMPOUNDS 637: PYRIDOPYRIMIDINEDIONES AS PDE4 INHIBITORS | 2008 |
|
RU2479584C2 |
MDM2 PROTEIN DESTRUCTORS | 2017 |
|
RU2743432C2 |
COMPOUND CONTAINING OXADIAZOLE AND A PHARMACEUTICAL COMPOSITION CONTAINING IT | 2019 |
|
RU2789456C2 |
TREATMENT METHOD | 2012 |
|
RU2621148C2 |
MEDICINAL COMPOUNDS | 2014 |
|
RU2691105C1 |
Authors
Dates
2019-07-03—Published
2014-07-10—Filed